Cross Atlantic Partners
VC Fund
New York, United States
Cross Atlantic Partners is a VC fund in New York focused on Health Care and Biotechnology. Cross Atlantic Partners (CAP) actively manages private equity funds for investment in developing healthcare and life sciences companies in the United States. They focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Cross Atlantic Partners invests in
Stages Cross Atlantic Partners invests in
Countries Cross Atlantic Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sandra Panem
|
|||
John L. Cassis
|
|||
Investment Focus
Industry
- Health Care 3 (33%)
- Biotechnology 3 (33%)
- Life Science 2 (22%)
- Manufacturing 2 (22%)
- Hospital 1 (11%)
Stage
- Series B 3 (33%)
- Series D 3 (33%)
- Series A 1 (11%)
- Series C 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sandra Panem
Owner
|
Owner | Total investments: 5 | Find email | |
|
John L. Cassis
Founding Partner
|
Founding Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Labcyte
|
Labcyte Inc. is a laboratory instrumentation company with a novel approach to dispensing small volumes of liquids for life sciences applications. The company's acoustic dispensing technology uses a focused beam of acoustic energy to eject nanoliter-scale droplets of fluid from one plate to another, with high accuracy atlow volumes and reduced consumables costs. In addition to DBL Investors, investors include Alloy Ventures, Abingworth, New Leaf Venture Partners, and Cross Atlantic Partners.Labcyte was founded in 2000 and is based in San Jose, California, United States. | $5.3M / Series D / Jan 08, 2013 | |
Sapphire Digital
|
Sapphire Digital empowers everyone to shop for their health care like an expert. Their integrated high-tech, high-touch platform helps people select better, more affordable care. Sapphire Digital leads the market with incentive and engagement programs proven to drive new levels of activation. Their solutions achieve measurable and sustainablesavings for consumers, employers and health plans. Over 280 million people each year rely on Vitals to help them decide on their care with confidence. | $4M / Series A / Oct 14, 2008 | |
|
Labcyte
|
Labcyte Inc. is a laboratory instrumentation company with a novel approach to dispensing small volumes of liquids for life sciences applications. The company's acoustic dispensing technology uses a focused beam of acoustic energy to eject nanoliter-scale droplets of fluid from one plate to another, with high accuracy atlow volumes and reduced consumables costs. In addition to DBL Investors, investors include Alloy Ventures, Abingworth, New Leaf Venture Partners, and Cross Atlantic Partners.Labcyte was founded in 2000 and is based in San Jose, California, United States. | $3.8M / Series C / Mar 26, 2008 | |
GQ Life Sciences
|
GQ Life Sciences, Inc. is a global life science information and search company. Formerly known as GenomeQuest, Inc., they changed their name in September of 2015 to highlight the fact that the product GenomeQuest has become a well-known brand within the industry. GQ Life Sciences is proud to offer its second major product, LifeQuest, alongside itsflagship GenomeQuest software. | $4M / Series B / Sep 24, 2007 | |
Medivance
|
Medivance, Inc. develops, manufactures, and sells temperature management products to hospitals worldwide. The company’s flagship product, the Arctic Sun Temperature Management System, enables clinicians to manage patient temperature in a noninvasive manner. It also offers clinical training in Targeted Temperature Management. The company was foundedin 1998 and is headquartered in Louisville, Colorado with a European office in Den Hague, the Netherlands. As of November 10, 2011, Medivance, Inc. operates as a subsidiary of Bard Medical, Inc. | $23M / Series D / Jul 27, 2007 | |
Confluent Surgical
|
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts. | $23M / Series D / Mar 31, 2005 | |
Acorda Therapeutics
|
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Companycompleted clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity. | $55.3M / Series B / May 20, 2003 | |
|
Confluent Surgical
|
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts. | $20M / Series C / Jun 25, 2002 | |
|
Medivance
|
Medivance, Inc. develops, manufactures, and sells temperature management products to hospitals worldwide. The company’s flagship product, the Arctic Sun Temperature Management System, enables clinicians to manage patient temperature in a noninvasive manner. It also offers clinical training in Targeted Temperature Management. The company was foundedin 1998 and is headquartered in Louisville, Colorado with a European office in Den Hague, the Netherlands. As of November 10, 2011, Medivance, Inc. operates as a subsidiary of Bard Medical, Inc. | $16M / Series B / Jun 18, 2001 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cross Atlantic Partners invest in?
Cross Atlantic Partners invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series B and Series D stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cross Atlantic Partners?
Public channels for Cross Atlantic Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cross Atlantic Partners?
The team at Cross Atlantic Partners includes Sandra Panem (Owner) and John L. Cassis (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
